LLY stock forecast, quote, news & analysis

Key Takeaways

• Eli Lilly shares pulled back roughly 8.6% over the trailing month, trading near $1,115 after peaking above $1,290 earlier in the period.
• The decline has been driven primarily by broader healthcare-sector softness and rotation away from high-multiple growth names rather than company-specific weakness.
• Fundamentals remain strong: second-quarter 2026 revenue rose 48% year over year to $22.97 billion, led by Mounjaro and Zepbound.
• Lilly raised full-year 2026 revenue guidance to $85–87 billion, and Wall Street maintains a broadly favorable "Moderate Buy" consensus.
• Near-term sentiment was dented by a rival's failed cardiovascular trial, even though the setback was not directly tied to Lilly's core franchise.

Current Market Snapshot

Eli Lilly and Company (NYSE: LLY) has traded defensively in recent weeks, with shares slipping below the $1,200 mark and settling near $1,115 as of the latest available session. The stock sits below its 50-day moving average of roughly $1,183 while remaining comfortably above its 200-day average near $1,071. Its 52-week range spans from about $712 to roughly $1,293, underscoring both the scale of its multi-year advance and the magnitude of the recent consolidation. With a market capitalization around $1 trillion, Lilly is among the largest healthcare companies in the world, and its valuation remains sensitive to shifts in sector sentiment and interest-rate expectations.

Eli Lilly (LLY) Business Overview and Competitive Position

Eli Lilly is a global pharmaceutical company focused on cardiometabolic health, oncology, immunology, and neuroscience. Its growth story is anchored by the GLP-1 franchise: Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for obesity, which together generated roughly $14.9 billion in second-quarter revenue. Beyond these blockbusters, the portfolio includes Jardiance, Trulicity, Verzenio, Taltz, Kisunla for Alzheimer's disease, and the newer oral GLP-1 pill Foundayo. Lilly has also built a deep pipeline, headlined by the next-generation obesity candidate retatrutide. Its leadership in the cardiometabolic space, expanding manufacturing capacity, and diversifying acquisitions position it as the dominant player in one of the industry's largest growth categories.

Recent Developments Driving LLY

Lilly's recent price action reflects a mix of strong fundamentals and external headwinds. The company reported second-quarter 2026 results in early August, delivering $22.97 billion in revenue (up 48% year over year) and non-GAAP earnings of $8.38 per share, while raising full-year revenue guidance to $85–87 billion. Mounjaro sales climbed 91% to $9.94 billion, and Zepbound rose 46% to $4.93 billion.

Several catalysts followed. The U.S. FDA expanded Mounjaro's label to include reducing the risk of heart attack and stroke in certain adults with type 2 diabetes, broadening its clinical relevance. Lilly's oral GLP-1 medicine Foundayo continued its U.S. launch after generating roughly $100 million in its first full quarter, and the Medicare GLP-1 Bridge Program that launched in July expanded obesity-drug coverage. On the corporate side, Lilly announced plans to acquire Novartis-linked Merida Biosciences for about $2.875 billion to bolster its autoimmune and allergy portfolio, and the FDA cleared a Roche-Lilly blood test to help identify Alzheimer's disease.

At the same time, sentiment was pressured by a late-stage trial failure from rival Novartis (NVS) in the Lp(a) cholesterol space, which rippled through the sector and raised questions about a competitive drug class. Broader rotation out of richly valued growth stocks, including megacap healthcare names, added further downward pressure even as Lilly's core demand metrics remained intact.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated look at algorithmic trading strategies across the market. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant robots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, giving traders a way to explore automated approaches tailored to different objectives. For investors interested in combining data-driven signals with their own research, this section is a practical starting point for discovering how AI-driven systems approach names across the healthcare sector and beyond.

2026 Outlook and What Investors Should Watch

Looking ahead, Lilly's trajectory will hinge on the continued scaling of its GLP-1 franchise. Key items to monitor include the rollout of Foundayo and its potential type 2 diabetes approval, the pace of manufacturing-capacity expansion, and the regulatory path for retatrutide, with a Biologics License Application submission anticipated in early 2027. Demand trends, reimbursement dynamics, and realized-price pressure on Mounjaro and Zepbound will also shape the top line, while competition from Novo Nordisk (NVO) and emerging oral obesity therapies remains a central variable. Macroeconomic factors such as interest-rate expectations could continue to influence sentiment toward high-multiple growth stocks. As always, outcomes are subject to clinical, regulatory, and competitive risks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations